Compare AdaptHealth Corp (AHCO) vs Deutsche Bank AG (DB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AdaptHealth Corp vs Deutsche Bank AG — how do they compare? AdaptHealth Corp trades at $5.66 (market cap $759.10M), while Deutsche Bank AG trades at $38.26 (market cap $72.15B). The key difference: Deutsche Bank AG is far larger — about 95× AdaptHealth Corp's market cap, and Deutsche Bank AG pays a 3.04% dividend while AdaptHealth Corp pays none. Which is the better fit depends on your goals.
| AHCO | DB | |
|---|---|---|
Market Cap | $759.10M | $72.15B |
Sector | Health | Financials |
52-Week High | $13.38 | $40.33 |
52-Week Low | $5.22 | $28.37 |
Enterprise Value | $2.78B | — |
Dividend Yield | — | 3.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AdaptHealth Corp. (AHCO) trades at $5.69, down 5.87% in the last 24 hours, reflecting negative sentiment after recent earnings misses and lowered guidance. The stock shows a bearish technical signal with support near $5, while fundamentals reveal revenue of $3.24 billion in 2025 but a net loss of $70.79 million, with profitability metrics like net margin at -6.82% indicating operational challenges. Recent news highlights multiple law firm investigations into potential securities fraud following disappointing Q2 2026 results.
The outlook for AHCO is cautious due to persistent earnings underperformance and rising costs from fixed-price contracts. While analyst consensus remains bullish with a $11.00 price target, significant risks include ongoing legal scrutiny, margin pressure, and execution uncertainties. Investors should weigh the high institutional buy ratings against fundamental weaknesses and recent negative developments.
Deutsche Bank (DB) trades at $38.06, up 1.14% with a bullish technical outlook supported by moving averages. The bank shows strong fundamentals with Q2 2026 revenue growth and a 10.02 P/E ratio trading below book value at 0.79. Recent developments include being named China's renminbi clearing bank and announcing a $500 million buyback. Net income margin improved to 22.04% in 2026, though Q2 earnings missed expectations.
DB presents a mixed investment case with attractive valuation metrics and strategic positioning in European banking, but faces execution risks from recent earnings miss and ongoing tax investigations. The stock trades at a discount to peers with moderate analyst support (21% buy rating) despite strong operational cash flow of $47.06 billion in 2025.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AdaptHealth Corp
AdaptHealth provides patient-centered healthcare-at-home solutions in the U.S. It offers medical equipment and supplies for sleep therapy, respiratory health, diabetes management, and general home wellness.
Read more on AHCO →About Deutsche Bank AG
In July 2019, Deutsche Bank announced another restructuring plan hoping to revitalize revenue, reduce costs, and return to profitability. The largest moving pieces of the new plan is the full exit of global equity sales & trading, the scaling back of its fixed income business, as well as 18,000 FTE reductions until 2022. The remaining core business segments include private banking, corporate banking, asset management, and investment banking.
Read more on DB →
